On Invalid Date, Revance Therapeutics (NASDAQ: RVNC) reported Q4 2023 earnings per share (EPS) of -$0.63, up 66.84% year over year. Total Revance Therapeutics earnings for the quarter were -$55.70 million. In the same quarter last year, Revance Therapeutics's earnings per share (EPS) was -$1.90.
As of Q1 2024, Revance Therapeutics's earnings has grown year over year. Revance Therapeutics's earnings in the past year totalled -$323.99 million.
What is RVNC's earnings date?
Revance Therapeutics's earnings date is Invalid Date. Add RVNC to your watchlist to be reminded of RVNC's next earnings announcement.
What was RVNC's revenue last quarter?
On Invalid Date, Revance Therapeutics (NASDAQ: RVNC) reported Q4 2023 revenue of $69.80 million up 39.82% year over year. In the same quarter last year, Revance Therapeutics's revenue was $49.92 million.
What was RVNC's revenue growth in the past year?
As of Q1 2024, Revance Therapeutics's revenue has grown 76.55% year over year. This is 92.75 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Revance Therapeutics's revenue in the past year totalled $234.04 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.